Back to News
Market Impact: 0.15
Lilly Study Shows Broader Biomarker Changes With Taltz-Zepbound Combination In Psoriasis
Source: Nasdaq
Healthcare & Biotech
Eli Lilly presented new exploratory data from its Phase 3b TOGETHER-PsO trial, examining the biological relationship between psoriasis and obesity and the potential impact of treating both conditions simultaneously. The article provides no specific results or quantified treatment effects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
LLY0.20
More News
- We’re still figuring out the side effects of GLP-1 weight-loss drugs
- Jim Cramer's top 10 things to watch in the stock market Friday
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down